Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: population-based nested case–control study

Hsien-Yi Wang,1,2 Charles Lung-Cheng Huang,3,4 I Jung Feng,5 Hui-Chun Tsuang6

ABSTRACT

Objectives The study aims to compare the risk of chronic kidney diseases (CKDs) between patients with schizophrenia using first- and second-generation antipsychotics.

Setting Datasets of 2000–2013 National Health Insurance in Taiwan were used.

Participants The National Health Insurance reimbursement claims data have been transferred to and managed by the National Health Research Institute in Taiwan since 1996. We used the Psychiatric Inpatient Medical Claims database, a subset of the National Health Insurance Research Database, comprising a cohort of patients hospitalised for psychiatric disorders between 2000 and 2013 (n=267,807). The database included patients with at least one psychiatric inpatient record and one discharge diagnosis of mental disorders coded by the International Classification of Diseases, Ninth Revision (ICD-9) codes 290–319. The age of patients at first admission was restricted to 18–65 years.

Primary outcome CKD (ICD-9 code 582, 583, 585, 586, 588) requiring hospitalisation or three outpatient visits. The diagnosis of CKD follows the criteria of ‘Kidney Disease: Improving Global Outcomes’ in Taiwan. CKD is defined as a kidney damage as albumin-to-creatinine ratio >30 mg/g in two of three spot urine specimens or glomerular filtration rate <60 mL/min/1.73 m² for 3 months or more.

Results We found that the risks for CKD were higher for those who used second-generation antipsychotics (SGAs) longer cumulatively than those who did not. Using non-users, patients did not have any SGA records, as reference group, the risks for CKD comparing those using SGAs for more than 1000 days were 1.42 (1.06–1.91) and 1.30 (1.13–1.51), respectively.

Conclusions The current study suggests the relationship between using SGAs and risk of CKD.

INTRODUCTION

Schizophrenia is a chronic mental illness with lifetime prevalence rate around 1%.1 2 Patients with schizophrenia have been shown to have an excess mortality, being two or three times as high as that in the general population.3–5 Cardiovascular diseases have an increased prevalence among patients with schizophrenia.6 Metabolic syndrome, a collection of visceral adiposity (measured by waist size), high-fasting glucose, increased blood pressure, elevated triglyceride levels and low high-density lipoprotein cholesterol levels,7 also seems to be a vital health problem to patients with schizophrenia.8 9 Furthermore, patients with schizophrenia are liable to develop diabetes mellitus (DM)10 10 and chronic kidney diseases (CKDs).11

The introduction of second-generation antipsychotics (SGAs) in the early 1990s was initially associated with better quality of life, lower rate of relapse and better tolerability than first-generation antipsychotics (FGAs).12–14 However, the superiority of SGAs has been criticised by subsequent studies.15 16 For example, the association between weight gain and use of SGAs, clozapine in particular, has been reported.17

More recent studies confirmed the above finding regarding the concern of using SGA medications. A study using the National Health Insurance Research Database in Taiwan18 found that use of clozapine,
quetiapine, olanzapine, zotepine and risperidone was associated with the increased risk of pneumonia. A nationwide German/Austrian Diabetes Survey, which recruited 60,162 teenagers with type 1 DM, demonstrated that subjects treated with SGAs, risperidone in particular, showed higher body mass index.\textsuperscript{19} A national study\textsuperscript{20} conducted in the USA compared 107,551 youths using SGAs with 1,221,434 youths who do not. The risk for incident DM was increased in youths taking SGAs. The risk was higher among those using ziprasidone and aripiprazole. However, the risk for incident type 2 DM was not associated with newer SGAs, quetiapine and olanzapine.

DM was one of risk factors to develop CKD.\textsuperscript{21} Besides, schizophrenia has been shown to be associated with an increased risk of CKD in a nationwide study in Taiwan.\textsuperscript{11} Therefore, we consider CKD to be included as an outcome variable, too. A population-based, nested case–control study was carried out here by applying the large national psychiatric database, the Psychiatric Inpatient Medical Claims database. Meanwhile, to provide a comprehensive picture of the risk of using antipsychotics, we compare people who used both first-generation antipsychotics (FGAs) and SGAs, people who use only SGAs with those who used only FGA drugs in our study.

METHODS

Study subjects

Taiwan started a single-payer National Health Insurance programme on 1 March 1995. The National Health Insurance reimbursement claims data have been transferred to and managed by the National Health Research Institute in Taiwan since 1996. The database includes medical claim files representative of the entire population in Taiwan. All investigators signed an agreement that guarantees patient confidentiality before using the data. We used the Psychiatric Inpatient Medical Claims database, a subset of the National Health Insurance Research Database, comprising a cohort of patients hospitalised for psychiatric disorders between 2000 and 2013 (n=267,807). The database included patients with at least one psychiatric inpatient record and one discharge diagnosis of mental disorders coded by the International Classification of Diseases, Ninth Revision (ICD-9) codes 290–319. The database includes patients’ demographic characteristics, diagnoses, medical expenditures and prescription claims data.\textsuperscript{22} Each prescription record contains type of medication, dosage, time of prescription and duration of drug supply. Information which could be used to identify beneficiaries and medical care providers were scrambled by the Bureau of National Health Insurance.\textsuperscript{23}

We enrolled patients with at least one psychiatric admission between 2000 and 2013 but no psychiatric admissions between 1996 and 1999 (n=136,644). The inclusion criteria for the study cohort was that one’s diagnosis at each discharge fulfilled the principal diagnosis of schizophrenia (ICD-9 code 295.**) if a patient had several psychiatric admissions. The age of patients at first admission was restricted to 18–65 years.

Case and control definition

In this study, we conducted a nested case–control study derived from the cohort. Patients with CKD (ICD-9 codes 582, 583, 585, 586, 588) requiring hospitalisation or three outpatient visits were selected as cases (n=34,111). The date of first hospitalisation for CKD or the third outpatient visit was defined as the index date. The diagnosis of CKD follows the criteria of ‘Kidney Disease: Improving Global Outcomes’ in Taiwan. CKD is defined as a kidney damage as albumin-to-creatinine ratio >30 mg/g in two of three spot urine specimens or glomerular filtration rate <60 mL/min/1.73 m\textsuperscript{2} for 3 months or more. For each case, three matched control subjects were randomly selected from the same patients with schizophrenia who have not been diagnosed with CKD before the index date. Control subjects were matched to the patients for age diagnosed with schizophrenia, gender and the year diagnosed with schizophrenia. Each control was assigned the index date of the corresponding case. The patients diagnosed with CKD before the schizophrenia diagnosis date were excluded.

Measurement of exposure

The data of antipsychotic drug use were derived from the prescription files. The duration of treatment was calculated using the dispensed number of units and the dosing regimen for each patient. SGA drugs used in our study included clozapine, olanzapine, quetiapine, zotepine, risperidone, amisulpride, ziprasidone, aripiprazole and paliperidone. FGA drugs used in our study included chlorpromazine, levomepromazine, fluphenazine, perphenazine, trifluoperazine, thioridazine, pipotiazine, haloperidol, moperone, flupentixol, clopenthixol, chlorprothixene, pimozide, loxapine, sulpiride, clozapine and penfluridol. Because this study focused on the associations between the individual SGA drug and the risk of CKD, all FGA drugs were grouped together in the data analysis. The follow-up period is from the schizophrenia diagnosis date to the index date.

Covariates

Age, gender and the duration of schizophrenia were controlled by the matching process of the study design.

Statistical analysis

For the comparisons of demographic between cases and controls, t test was used for continuous variables and $\chi^2$ tests for discrete variables. Univariate and multivariable conditional logistic regressions were used to estimate the associations between the exposure to antipsychotic use and risk of CKD. Comorbidity factors, such as DM, congestive heart failure, myocardial infarction, stroke, hyperlipidaemia, hypercholesterolaemia, hypertiglycireidaemia, hypertension and obesity were entered into adjusted model. ORs with 95% CIs were calculated. A $p$ value of 0.05 was considered significant.
With the adjustment of comorbidity factors, the analysis results showed that greater risks of CKD for patients who received SGA than patients who did not receive as the reference group. Especially, patients cumulatively used SGA 90–180 days and more than 1000 days have 42% and 30% significantly higher odds of developing CKD compared with the reference group (adjusted OR (95% CI)=1.42 (1.06 to 1.91), 1.30 (1.13 to 1.51)) (table 3). Patients who used olanzapine, quetiapine, zotepine or risperidone all displayed greater odds of developing CKD than the reference group. Patients with quetiapine exposure have statistically significant higher risk than the reference group.

### DISCUSSION

We found that the risks for CKD for those who used SGAs longer cumulatively were higher than those who did not. In addition, those who used only FGAs and those who used both SGAs and FGAs seemed to have lower risk for CKD.

Also using the dataset of Taiwan National Health Insurance, Tzeng et al found that neither FGAs nor SGAs increased the risk of CKD. However, the study design of Tzeng et al and ours varied a lot. First, we focused on in patients while Tzeng et al recruited patients with a first-time diagnosis of schizophrenia. Second, subjects of Tzeng et al were tracked for 3 years or the end of 2010 from the initial diagnosis date until the date of CKD diagnosis. We tracked subjects for longer period with one group tracked for 180–1000 days and another for period longer than 1000 days.

The introduction of SGAs in the early 1990s was initially shown better quality of life, lower rate of relapse and better tolerability than FGAs for patients of schizophrenia but has been criticised by other studies. The risk of pneumonia in inpatients with schizophrenia was examined using the National Health Insurance Research Database in Taiwan from 2000 to 2008. They found that the current use of clozapine, one kind of SGAs, was associated with a dose-dependent increase in the risk of pneumonia for inpatients with schizophrenia. In addition, other kinds of SGAs, including quetiapine, olanzapine, zotepine and risperidone were associated with increased risk of pneumonia while no clear dose-dependent

### Table 1 Basic characteristics of the study population

| Characteristic         | Cases (n=3411) n (%) | Controls (n=10233) n (%) |
|------------------------|----------------------|-------------------------|
| Age (mean±SD years)    | 41.1±10.2            | 41.1±10.2               |
| Male                   | 1871 (54.9)          | 5613 (54.9)             |
| Follow-up duration     | 7.71±4.71            | 7.71±4.71               |
| Comorbidities          |                      |                         |
| Diabetes mellitus*     | 1299 (38.1)          | 1006 (9.8)              |
| Congestive heart failure* | 207 (6.1)          | 86 (0.8)                |
| Myocardial infarction* | 41 (1.2)             | 23 (0.2)                |
| Stroke*                | 220 (6.5)            | 195 (1.9)               |
| Hyperlipidaemia*       | 502 (14.7)           | 433 (4.2)               |
| Hypercholesterolaemia* | 111 (3.3)            | 90 (0.9)                |
| Hypertriglyceridaemia* | 86 (2.5)             | 62 (0.6)                |
| Hypertension*          | 1232 (36.1)          | 1147 (11.2)             |
| Obesity*               | 49 (1.4)             | 37 (0.4)                |

*P<0.0001.

### Table 2 Comparison of crude and adjusted OR for CKD among types of antipsychotics by conditional logistic regression

| Drug used          | CKD cases (n=3411) | Controls (n=10233) | OR (95% CI)         | P value | AOR* (95% CI) | P value |
|--------------------|--------------------|--------------------|---------------------|---------|---------------|---------|
| No FGA, no SGA     | 3                  | 17                 | 0.76 (0.22 to 2.59) | 0.6570  | 0.53 (0.13 to 2.21) | 0.3857  |
| FGA alone          | 300                | 1278               | 1                   | 1       | —             | —       |
| SGA alone          | 26                 | 102                | 1.10 (0.70 to 1.72) | 0.6920  | 1.06 (0.65 to 1.74) | 0.8086  |
| Combination        | 3082               | 8827               | 1.50 (1.32 to 1.71) | <0.0001 | 1.28 (1.11 to 1.47) | 0.0009  |

*AAdjusted for diabetes mellitus, congestive heart failure, myocardial infarction, stroke, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, hypertension and obesity.

AOR, adjusted OR; CKD, chronic kidney disease; FGA, first-generation antipsychotic; SGA, second-generation antipsychotic.
relationship was found. They suggested that patients with schizophrenia who used these antipsychotics were to be monitored for pneumonia. Our study further suggests that inpatients with schizophrenia were being monitored for CKD, since we found that the risks for CKD were higher for those who used SGAs longer cumulatively than those who did not. Similar to the findings of Kuo et al, we did not see dose-dependent relationship SGAs and risk of CKD.

The increasing prevalence of end-stage renal disease (ESRD) has been a global challenge. In the USA, CKDs are the nation’s ninth leading cause of death. In Taiwan, CKDs have been the eighth leading cause of death since 1997 and was still the 10th leading cause of death.

### Table 3  Overall cumulative period of using SGAs

| Period of SGA use | CKD cases (n=3411) | Controls (n=10233) | OR (95% CI) | P value | AOR* (95% CI) | P value |
|------------------|--------------------|--------------------|-------------|---------|----------------|---------|
| Cumulative SGA use |                    |                    |             |         |                |         |
| Non-users        | 303                | 1304               | 1           |         | 1.20 (0.95 to 1.51) | 0.1247 |
| 0<period≤ 90     | 177                | 552                | 1.38 (1.12 to 1.71) | 0.0026 | 1.43 (1.20 to 1.81) | 0.0002 |
| 90<period≤ 180   | 92                 | 241                | 1.65 (1.26 to 2.16) | 0.0003 | 1.47 (1.06 to 1.91) | 0.0208 |
| 180<period≤ 1000 | 409                | 1271               | 1.39 (1.17 to 1.64) | 0.0001 | 1.19 (0.99 to 1.43) | 0.0654 |
| 1000>period      | 2430               | 6865               | 1.53 (1.34 to 1.75) | <0.0001 | 1.30 (1.13 to 1.51) | 0.0004 |
| Cumulative clozapine use (days) | | |             |         |                |         |
| Non-users        | 2318               | 7215               | 1           |         | 1.14 (1.02 to 1.27) | 0.0181 |
| 0<period≤ 90     | 183                | 351                | 1.63 (1.35 to 1.96) | <0.0001 | 1.48 (1.20 to 1.81) | 0.0002 |
| 90<period≤ 180   | 49                 | 140                | 1.09 (0.79 to 1.52) | 0.6057 | 0.91 (0.63 to 1.32) | 0.6281 |
| 180<period≤ 1000 | 178                | 549                | 1.01 (0.85 to 1.20) | 0.9901 | 0.94 (0.77 to 1.14) | 0.5099 |
| 1000>period      | 683                | 1978               | 1.08 (0.98 to 1.19) | 0.1456 | 1.14 (1.02 to 1.27) | 0.0181 |
| Cumulative olanzapine use (days) | | |             |         |                |         |
| Non-users        | 2046               | 6465               | 1           |         | 1.48 (1.20 to 1.81) | 0.0002 |
| 0<period≤ 90     | 396                | 1018               | 1.23 (1.09 to 1.40) | 0.0012 | 1.18 (1.02 to 1.35) | 0.0225 |
| 90<period≤ 180   | 156                | 344                | 1.44 (1.18 to 1.75) | 0.0003 | 1.37 (1.11 to 1.70) | 0.0039 |
| 180<period≤ 1000 | 401                | 1038               | 1.22 (1.08 to 1.39) | 0.0017 | 1.15 (1.00 to 1.32) | 0.0561 |
| 1000>period      | 412                | 1368               | 0.95 (0.85 to 1.08) | 0.4401 | 1.05 (0.92 to 1.19) | 0.4954 |
| Cumulative quetiapine use (days) | | |             |         |                |         |
| Non-users        | 1669               | 6198               | 1           |         | 1.36 (1.19 to 1.57) | <0.0001 |
| 0<period≤ 90     | 399                | 967                | 1.54 (1.35 to 1.75) | <0.0001 | 1.36 (1.19 to 1.57) | <0.0001 |
| 90<period≤ 180   | 147                | 356                | 1.54 (1.26 to 1.88) | <0.0001 | 1.27 (1.02 to 1.58) | 0.0358 |
| 180<period≤ 1000 | 534                | 1180               | 1.69 (1.50 to 1.89) | <0.0001 | 1.48 (1.30 to 1.68) | <0.0001 |
| 1000>period      | 662                | 1532               | 1.61 (1.45 to 1.79) | <0.0001 | 1.44 (1.28 to 1.62) | <0.0001 |
| Cumulative zotepine use (days) | | |             |         |                |         |
| Non-users        | 2292               | 7375               | 1           |         | 1.26 (1.08 to 1.47) | 0.0038 |
| 0<period≤ 90     | 319                | 743                | 1.38 (1.20 to 1.59) | <0.0001 | 1.26 (1.08 to 1.47) | 0.0038 |
| 90<period≤ 180   | 120                | 265                | 1.46 (1.17 to 1.82) | 0.0008 | 1.27 (0.99 to 1.63) | 0.0592 |
| 180<period≤ 1000 | 310                | 770                | 1.30 (1.13 to 1.49) | 0.0003 | 1.16 (1.00 to 1.36) | 0.0572 |
| 1000>period      | 370                | 1080               | 1.11 (0.97 to 1.26) | 0.1240 | 1.00 (0.87 to 1.15) | 0.9854 |
| Cumulative risperidone use (days) | | |             |         |                |         |
| Non-users        | 896                | 3056               | 1           |         | 1.14 (0.98 to 1.33) | 0.0927 |
| 0<period≤ 90     | 396                | 1078               | 1.26 (1.09 to 1.44) | 0.0012 | 1.14 (0.98 to 1.33) | 0.0927 |
| 90<period≤ 180   | 207                | 511                | 1.39 (1.16 to 1.66) | 0.0003 | 1.26 (1.03 to 1.53) | 0.0220 |
| 180<period≤ 1000 | 733                | 2028               | 1.24 (1.10 to 1.38) | 0.0002 | 1.12 (0.99 to 1.26) | 0.0845 |
| 1000>period      | 1179               | 3560               | 1.13 (1.03 to 1.25) | 0.0148 | 1.10 (0.99 to 1.23) | 0.0756 |

*Adjusted for diabetes mellitus, congestive heart failure, myocardial infarction, stroke, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, hypertension and obesity.

AOR, adjusted OR; CKD chronic kidney disease; SGA, second-generation antipsychotic.
recently. 25 Meanwhile, the high prevalence of CKD might contribute to the high prevalence of ESRD in Taiwan. 26 Our finding that inpatients with schizophrenia who used SGAs longer have higher risks for CKD than those who did not reminds this population being monitored for CKD.

Some limitations need to be considered in the current study. First, because our data source is from a claim data set, it is hard to know how much medication each patient really took. Second, we cannot include variables not captured in the claimed database, such as patients’ lifestyle and family history. However, the current study suggests a further study on the relationship between using SGAs and risk of CKD.

Acknowledgements The authors thank the Bureau of National Health Insurance and National Health Institutes for making available the databases for this study.

Contributors H-CT and H-YW initiated the study. H-CT, H-YW and CL-CH designed the study. LJF analysed the data. H-CT wrote the manuscript and H-YW, CL-CH and LJF approved the final manuscript.

Funding This study was funded by Chi-Mei Medical Center (grant number: CMFHR 10557).

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Datasets of National Health Insurance in Taiwan were used. All investigators should sign an agreement that guarantees patient confidentiality before using the data.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Chien IC, Hsu JH, Lin CH, et al. Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr Res 2009;111:17–22.
2. Hovatta I, Terwilliger JD, Lichtermer D, et al. Schizophrenia in the genetic isolate of Finland. Am J Med Genet 1997;74:353–60.
3. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502–8.
4. Brown S, Kim M, Mitchell C, et al. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010;196:116–21.
5. Osby U, Correia N, Brandt L, et al. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000;321:489–4.
6. Capasso RM, Lineberry TW, Bostwick JM, et al. Mortality in schizophrenia and schaofaective disorder: an Olmsted County, Minnesota cohort: 1990-2005. Schizophr Res 2008;98:287–94.
7. Grundy SM, Cleeman JI, Danilis SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52.
8. Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia: depression and bipolar disorder. World Psychiatry 2015;14:119–36.
9. Manu P, Dima L, Shulman M, et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand 2015;132:97–108.
10. Sallach SA, Bell S, Kimani S, et al. Risk for incident diabetes—effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 2008;117:342–7.
11. Tseng NS, Hsu YH, Ho SY, et al. Is schizophrenia associated with an increased risk of chronic kidney disease? A nationwide matched-cohort study. BMJ Open 2015;5:e006777.
12. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004;18:877–93.
13. Leucht S, Barnes TR, Kissling W. Relapse prevention with schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209–22.
14. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581–9.
15. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CULASS 1). Arch Gen Psychiatry 2006;63:1079–87.
16. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23.
17. Baddour LM, Lin CC, Chen CY, et al. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. J Clin Psychiatry 2011;72:751–6.
18. Kuo CJ, Yang SY, Liao YT, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 2013;39:648–57.
19. Galler A, Bollow E, Meusers M, et al. Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV). Diabetes Care 2015;38:1051–7.
20. Rubin DM, Kreider AR, Matone M, et al. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. JAMA Pediatr 2015;169:e150285.
21. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventative care of chronic kidney disease in Taiwan. Nephrololology 2010;15 Suppl 2(Suppl 2):3–9.
22. Gau CS, Chang CJ, Tsai FJ, et al. Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched case-control study. Bipolar Disord 2010;12:253–63.
23. Gau SS, Chung CH, Gau CS. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. J Clin Psychopharmacol 2008;28:271–8.
24. Arias E, Anderson RN, Kung HC, et al. Deaths: final data for 2001. Natl Vital Stat Rep 2003;52:1–115.
25. Department of Health. Department of Health: Health and Vital Statistics Republic of China 2017. Taiwan, ROC, 2017.
26. Hsu CC, Hwang SJ, Wen CP, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis 2006;48:727–38.